Drugs / Rulonilimab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06755515 | Sep 2024 → Sep 2028 expected | cervical cancer | Shandong New Time Pharmaceutical Co., LTD | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT05408221 | Nov 2022 → Aug 2025 overdue | hepatocellular carcinoma | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rulonilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05408221 ↗ |
| Route | Intravenous | “Rulonilimab, intravenous (i.v.) administration every 3 weeks” NCT05408221 ↗ |